Results 81 to 90 of about 3,283 (198)

Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy

International ophtalmology
Neovascular age-related macular degeneration (nAMD) is a major cause of vision loss in older adults. While anti-VEGF therapies have improved management by suppressing abnormal blood vessel growth, a substantial subset of patients show poor functional as ...
Nathalie Bleidißel, Matthias Weichenberger, M. Maier, Nina Spielberg, N. Feucht   +4 more
semanticscholar   +1 more source

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, Volume 54, Issue 5, Page 724-726, July 2026.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

Sorprendente regresión completa de una membrana neovascular coroidea con faricimab

Retinografía de DMAEnv antes y después del tratamiento. En la OCT estructural y la OCTA se aprecia MNC tipo1 activa. Se inicia tratamiento con anti-VEGF (proteína de fusión contra VEGF-A, VEGF-B y PIGF) en pauta T&E con control de la exudación ...
Duch Samper, Antonio Miguel, Ruiz del Rio, Noemí, García Ibor, Francisca   +2 more
core   +1 more source

Short-term real-world outcomes of diabetic macular edema treated with intravitreal faricimab

PLoS ONE
Faricimab, a new drug for diabetic macular edema (DME), was made available in Japan in 2022. However, few reports have been published about its treatment outcomes in clinical practice.
Toshiaki Hirakata, Fumihiro Hara, Yuta Nochi, Daisuke Shinohara, Shutaro Yamamoto, Yoshimune Hiratsuka, S. Nakao   +6 more
semanticscholar   +1 more source

Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab

, 2020
This review summarizes the latest findings in the literature of Angiopoietin-2 (Ang-2), Tyrosine-protein kinase receptor (Tie-2) complex, and faricimab along with their involvement for the treatment of retinal vascular diseases in various clinical trials.
Tayeb Abbas, Majid Khan, Noah A. Shafi, Arshad M. Khanani, Aamir A. Aziz   +4 more
core   +1 more source

Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA

International Journal of Retina and Vitreous
To analyze the therapeutic response to faricimab 6 mg/0.05 ml in eyes with neovascular AMD (nAMD) with refractory intra- and/or subretinal fluid due to choroidal neovascularization (CNV), previously unresponsive to 4 mg monthly aflibercept and ...
A. Heinke, Alexandra Warter, Ines D. Nagel, A. Agnihotri, N. Mehta, C. Galang, Daniel N. Deussen, Dirk-Uwe G. Bartsch, Ling-Yun Cheng, Henry Ferreyra, William R. Freeman   +10 more
semanticscholar   +1 more source

Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema

American Journal of Ophthalmology Case Reports
Purpose: More information is emerging on faricimab-svoa (faricimab) used for etiologies beyond wet age-related macular degeneration (AMD) and diabetic macular edema (DME), including ongoing trials for use in macular edema following retinal vein occlusion
Justin Hanson, Marcus Yamamoto, Edmund Tsui, Irena Tsui   +3 more
doaj   +1 more source

Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion

International Journal of Retina and Vitreous
Faricimab, the new anti-vascular endothelial growth factor (VEGF) drug including a bispecific antibody targeting both VEGF-A and angiopoietin-2 (Ang-2), has emerged as a therapeutic option for macular edema secondary to retinal vein occlusion (RVO), and ...
Toshiaki Hirakata, Ai Toride, Kenta Ashikaga, Takanori Nakagawa, Fumihiro Hara, Yuta Nochi, Shutaro Yamamoto, Yoshimune Hiratsuka, S. Nakao   +8 more
semanticscholar   +1 more source

Intravitreal faricimab as an adjuvant in the management of tubercular uveitis

PURPOSE: To report the use of intravitreal faricimab used as an adjunct in the management of intraocular tuberculosis (IOTB) in a patient with occlusive retinal vasculitis (ORV) and choroiditis. METHODS: A case report.
Julian, Karina, Amrani, Sarah, Bonilla, M Fernanda, Mohamed, Ali, Agarwal, Aniruddha, Alcibahy, Yasmine   +5 more
core   +1 more source

Real-world use of faricimab to treat DME patients in the UK

Purpose (463 characters)Faricimab, a bispecific antibody inhibiting Angiopoietin-2 (Ang2) and Vascular Endothelial Growth Factor (VEGF)-A, was approved in the UK on May 17, 2022 for the treatment of DME.
Shah, Parth, McGrory, Sarah, Gale, Richard P., Lotery, Andrew, De Salvo, Gabriella, Kiire, Christine, Sivaprasad, Sobha, Peto, Tunde, Downey, Louise, Dodds, Melanie, Chi, Gloria, Reynolds, Rhianon, James, Natalee, Downey, Amanda, Pearce, Ian, Talks, James Stephen, Bailey, Clare   +16 more
core   +1 more source